Small molecule · developed by Rigel Pharmaceuticals
R788 (tamatinib fosdium) is an orally administered agent studied in rheumatoid arthritis, dosed at 50, 100 or 150 mg twice daily.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00326339 | Phase 2 | Rheumatoid Arthritis | Completed | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Rheumatoid Arthritis
Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.
See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RIGL catalysts and pipeline →